TOS.TO - TSO3 Inc.

Toronto - Toronto Delayed Price. Currency in CAD
0.44
-0.01 (-2.22%)
At close: 3:58PM EST
Stock chart is not supported by your current browser
Previous Close0.45
Open0.46
Bid0.43 x 0
Ask0.47 x 0
Day's Range0.43 - 0.47
52 Week Range0.39 - 2.83
Volume104,200
Avg. Volume124,644
Market Cap41.118M
Beta (3Y Monthly)3.46
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • ACCESSWIRE2 days ago

    Today's Research Reports on TSO3, Emerald Health Therapeutics, Emblem and BELLUS Health

    NEW YORK, NY / ACCESSWIRE / November 16, 2018 / MarketEdge Report strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with ...

  • PR Newswire3 days ago

    American Journal of Infection Control publishes TSO3 study on terminal sterilization of duodenoscopes

    QUÉBEC CITY, QC and MYRTLE BEACH, SC, Nov. 15,  2018 /PRNewswire/ - TSO3 Inc. ("TSO3" or the "Company") (TOS.TO), an innovator in sterilization technology for medical devices in healthcare settings, announces today that the results of the Company's clinical in-use and simulated use testing of the terminal sterilization of duodenoscopes have been published in the American Journal of Infection Control.  The paper describes innovative testing methods developed and deployed by the Company in support of its STERIZONE® VP4 Sterilizer, which has received a 510(k) clearance from the U.S. Food and Drug Administration (FDA), for terminal sterilization of multi-channeled, flexible endoscopes that fall within the specified indications for use, including duodenoscopes.

  • CNW Group3 days ago

    American Journal of Infection Control publishes TSO3 study on terminal sterilization of duodenoscopes

    QUÉBEC CITY, QC and MYRTLE BEACH, SC , Nov. 15,  2018 /CNW Telbec/ - TSO3 Inc. ("TSO3" or the "Company") (TOS.TO), an innovator in sterilization technology for medical devices in healthcare settings, announces today that the results of the Company's clinical in-use and simulated use testing of the terminal sterilization of duodenoscopes have been published in the American Journal of Infection Control.  The paper describes innovative testing methods developed and deployed by the Company in support of its STERIZONE® VP4 Sterilizer, which has received a 510(k) clearance from the U.S. Food and Drug Administration (FDA), for terminal sterilization of multi-channeled, flexible endoscopes that fall within the specified indications for use, including duodenoscopes.

  • PR Newswire12 days ago

    TSO3 Reports Third Quarter 2018 Results

    QUEBEC CITY and MYRTLE BEACH, SC , Nov. 6, 2018 /PRNewswire/ - TSO3 Inc. (TSX: TOS) ("TSO 3 " or the "Company"), an innovator in sterilization technology for medical devices in healthcare ...

  • CNW Group12 days ago

    TSO3 Reports Third Quarter 2018 Results

    TSO3 Reports Third Quarter 2018 Results

  • PR Newswire19 days ago

    TSO3 Awarded Low Temperature Sterilization Contract pursuant to a Quebec Tender

    MYRTLE BEACH, SC and QUEBEC CITY, Oct. 30, 2018 /PRNewswire/ - TSO3 Inc. (TOS.TO) ("TSO3" or the "Company"), an innovator in sterilization technology for medical devices in healthcare settings, announced that the Company has been awarded a sole-source contract relating to a low temperature sterilizer Request for Proposal (or tender) in the Province of Quebec for its STERIZONE® VP4 Sterilizers. "We are pleased to be able to provide value and serve the needs of hospitals in our home province of Quebec," stated R.M. (Ric) Rumble, TSO3's President and CEO.

  • CNW Group19 days ago

    TSO3 Awarded Low Temperature Sterilization Contract pursuant to a Quebec Tender

    MYRTLE BEACH , SC and QUEBEC CITY , Oct. 30, 2018 /CNW Telbec/ - TSO3 Inc. (TOS.TO) ("TSO3" or the "Company"), an innovator in sterilization technology for medical devices in healthcare settings, announced that the Company has been awarded a sole-source contract relating to a low temperature sterilizer Request for Proposal (or tender) in the Province of Quebec for its STERIZONE® VP4 Sterilizers. "We are pleased to be able to provide value and serve the needs of hospitals in our home province of Quebec ," stated R.M. ( Ric) Rumble , TSO3's President and CEO.

  • CNW Group20 days ago

    TSO3 Named Winner of South Carolina Innovation Award

    MYRTLE BEACH, SC and QUEBEC CITY , Oct. 29, 2018 /CNW Telbec/ - TSO3 Inc. (TOS.TO) ("TSO3" or the "Company"), an innovator in sterilization technology for medical devices in healthcare settings, was named the winner of the South Carolina Chamber of Commerce's SC Branded Product Innovation Award. This award follows the FDA clearance of the Company's paradigm-shifting STERIZONE® VP4 Sterilizer to terminally sterilize multi-channeled flexible endoscopes in healthcare settings.

  • PR Newswire20 days ago

    TSO3 Named Winner of South Carolina Innovation Award

    MYRTLE BEACH, SC and QUEBEC CITY, Oct. 29, 2018 /PRNewswire/ - TSO3 Inc. (TOS.TO) ("TSO3" or the "Company"), an innovator in sterilization technology for medical devices in healthcare settings, was named the winner of the South Carolina Chamber of Commerce's SC Branded Product Innovation Award. This award follows the FDA clearance of the Company's paradigm-shifting STERIZONE® VP4 Sterilizer to terminally sterilize multi-channeled flexible endoscopes in healthcare settings.

  • PR Newswire24 days ago

    TSO3 to Report Third Quarter 2018 Results on Wednesday, November 7, 2018

    QUEBEC CITY and MYRTLE BEACH, SC , Oct. 25, 2018 /PRNewswire/ - TSO 3 Inc. (TSX: TOS), ("TSO 3 " or the "Company"), an innovator in sterilization technology for medical devices in healthcare ...

  • CNW Group24 days ago

    TSO3 to Report Third Quarter 2018 Results on Wednesday, November 7, 2018

    TSO3 to Report Third Quarter 2018 Results on Wednesday, November 7, 2018

  • ACCESSWIRElast month

    Today's Research Reports on TSO3, Emerald Health Therapeutics, Emblem and BELLUS Health

    NEW YORK, NY / ACCESSWIRE / October 17, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • CNW Grouplast month

    TSO3 Provides a Commercialization Update

    The Company has hired a sales leader and supplemented its team of direct sales representatives with three independent sales organizations that have been trained and are actively quoting business in key territories.

  • PR Newswirelast month

    TSO3 Provides a Commercialization Update

    The Company has hired a sales leader and supplemented its team of direct sales representatives with three independent sales organizations that have been trained and are actively quoting business in key territories.

  • ACCESSWIRE2 months ago

    Today's Research Reports on Hemostemix, TSO3, Emerald Health Therapeutics and DiaMedica Therapeutics

    NEW YORK, NY / ACCESSWIRE / September 18, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • CNW Group3 months ago

    TSO3 Appoints Martin J. Madden to the Board of Directors

    TSO3 Appoints Martin J. Madden to the Board of Directors

  • ACCESSWIRE3 months ago

    Today's Research Reports on CRH Medical, TSO3, Emerald Health Therapeutics, and DiaMedica Therapeutics

    NEW YORK, NY / ACCESSWIRE / August 20, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • PR Newswire3 months ago

    UCHealth performs first patient procedure in Colorado using STERIZONE® technology

    LOVELAND, CO, MYRTLE BEACH, SC, and QUEBEC CITY, Aug. 20, 2018 /PRNewswire/ - TSO3 Inc. (TOS.TO) ("TSO3" or the "Company"), an innovator in sterilization technology for medical devices in healthcare settings, joins with UCHealth, a nationally recognized, nonprofit network of 10 acute care hospitals and more than 150 clinics throughout Colorado, southern Wyoming and western Nebraska, in announcing the first patient procedure in Colorado performed with a duodenoscope sterilized using the STERIZONE® technology.

  • CNW Group3 months ago

    UCHealth performs first patient procedure in Colorado using STERIZONE® technology

    LOVELAND, CO , MYRTLE BEACH, SC , and QUEBEC CITY , Aug. 20, 2018 /CNW/ - TSO3 Inc. (TOS.TO) ("TSO3" or the "Company"), an innovator in sterilization technology for medical devices in healthcare settings, joins with UCHealth, a nationally recognized, nonprofit network of 10 acute care hospitals and more than 150 clinics throughout Colorado , southern Wyoming and western Nebraska, in announcing the first patient procedure in Colorado performed with a duodenoscope sterilized using the STERIZONE® technology.

  • CNW Group3 months ago

    TSO3 Reports Second Quarter 2018 Results

    TSO3 Reports Second Quarter 2018 Results

  • PR Newswire3 months ago

    TSO3 Reports Second Quarter 2018 Results

    QUEBEC CITY and MYRTLE BEACH , United States , Aug. 7, 2018 /PRNewswire/ - TSO 3 Inc. (TSX: TOS) ("TSO 3 " or the "Company"), an innovator in sterilization technology for medical devices ...

  • CNW Group4 months ago

    TSO3 Announces Closing of US$20 million Financing with Courage Capital to Commercialize the STERIZONE® VP4 Sterilizer and Support Getinge Transition

    TSO3 Announces Closing of US$20 million Financing with Courage Capital to Commercialize the STERIZONE® VP4 Sterilizer and Support Getinge Transition

  • PR Newswire4 months ago

    TSO3 Announces Closing of US$20 million Financing with Courage Capital to Commercialize the STERIZONE® VP4 Sterilizer and Support Getinge Transition

    MYRTLE BEACH , SC and QUEBEC CITY , Aug. 1, 2018 /PRNewswire/ - TSO 3 Inc. (TSX: TOS) ("TSO 3 " or the "Company"), an innovator in sterilization technology for medical devices, today ...

  • CNW Group4 months ago

    TSO3 to Report Second Quarter 2018 Results on Wednesday, August 8, 2018

    QUEBEC CITY and MYRTLE BEACH, SC , July 30, 2018 /CNW Telbec/ - TSO3 Inc. (TOS.TO), ("TSO3" or the "Company"), an innovator in sterilization technology for medical devices in healthcare settings, will hold a conference call on Wednesday, August 8, 2018 to discuss its financial results for the second quarter ended June 30, 2018 .

  • ACCESSWIRE4 months ago

    Today's Research Reports on Centric Health, CRH Medical, TSO3 and Knight Therapeutics

    NEW YORK, NY / ACCESSWIRE / July 19, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...